Median PFS was significantly longer in patients with WT versus MT KRAS tumours, 10.9 months versus 9.4 months (p = 0.0038; HR: 1.40; 95% CI: 1.12–1.77) (Figure 2A). The gene discussed is KRAS; the disease is neoplasm.